[{"id":"d48caaad-9e1c-4582-bdcc-babff0358009","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334329","created_at":"2022-04-19T23:54:01.117Z","updated_at":"2024-07-02T16:35:00.260Z","phase":"Phase 1","brief_title":"Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT05334329","lead_sponsor":"City of Hope Medical Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cyclophosphamide • fludarabine IV • CYTO NK-102"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 07/20/2022","start_date":" 07/20/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-29"}]